Literature DB >> 14711075

Clinical pharmacodynamics of quinolones.

Paul G Ambrose1, Sujata M Bhavnani, Robert C Owens.   

Abstract

An understanding of fundamental PK-PD principles forms the basis for the rational use of antimicrobial agents. For quinolones, the fAUC24:MIC ratio is predictive of efficacy in animal and in vitro infection models, and in infected patients. The magnitude of the fAUC24:MIC ratio predictive of efficacy in animal and in vitro infection models has been shown to be concordant with those obtained from human data. By accounting for PK and microbiologic variability together with PK-PD targets associated with efficacy or resistance suppression by Monte Carlo simulation, it is possible to discriminate between therapeutic regimens and select those regimens likely to be of greater benefit to patients. The maturation of antimicrobial PK-PD as a scientific discipline continues to accelerate and currently impacts clinical practice, drug development, and regulatory decision making.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711075     DOI: 10.1016/s0891-5520(03)00061-8

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  16 in total

1.  Population pharmacokinetic model for gatifloxacin in pediatric patients.

Authors:  Christopher M Rubino; Edmund V Capparelli; John S Bradley; Jeffrey L Blumer; Gregory L Kearns; Michael Reed; Richard F Jacobs; Brenda Cirincione; Dennis M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.

Authors:  Kristina Öbrink-Hansen; Tore Forsingdal Hardlei; Birgitte Brock; Søren Jensen-Fangel; Marianne Kragh Thomsen; Eskild Petersen; Mads Kreilgaard
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

Review 3.  Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

Authors:  Christopher M Rubino; John S Bradley
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.

Authors:  Manjunath P Pai; Piergiorgio Cojutti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 6.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

7.  Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.

Authors:  Brent M Booker; Patrick F Smith; Alan Forrest; Julie Bullock; Pamela Kelchlin; Sujata M Bhavnani; Ronald N Jones; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  Population Pharmacokinetics of Moxifloxacin in Children.

Authors:  Rachel G Greenberg; Cornelia B Landersdorfer; Nazario Rivera-Chaparro; Melissa Harward; Thomas Conrad; Aya Nakamura; Carl M Kirkpatrick; Kenan Gu; Varduhi Ghazaryhan; Blaire Osborn; Emmanuel B Walter
Journal:  Paediatr Drugs       Date:  2022-03-14       Impact factor: 3.022

Review 9.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 10.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.